Short answer
Sana Biotechnology, Inc. (SANA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- $20M
- +148.4% YoY · +132.1% QoQ
- EPS (diluted)
- $0.08
- +153.3% YoY · +136.4% QoQ
Source: XBRL data from the Sana Biotechnology, Inc. (SANA) Q3 2026 10-Q on SEC EDGAR. USD.
Sana Biotechnology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net income $20.4M vs net loss $42.2M YoY, driven by $63.4M contingent consideration gain
- R&D expense $33.9M, up $3.8M YoY, driven by SC451 and SG293 manufacturing costs
- Cash, equivalents and securities $121.7M; nine-month operating cash use $108.9M
- Outlook: additional capital needed within 12 months, substantial going-concern doubt, SC451 and SG293 prioritized
Risk Factors
- New H-1B visa risk, triggered by a new one-time $100,000 fee for new petitions and proposed program reforms
- Portfolio prioritization risk, November 2025 suspension of SC291 and SC262 development reduced pipeline breadth and increased reliance on SC451 and SG293
- Regulatory risk, FDA boxed-warning scrutiny for CAR T malignancies could impose additional requirements on in vivo CAR T programs
- Operational risk, limited NHP model availability has delayed preclinical studies and increased costs
- Financial risk, substantial losses and going-concern uncertainty create dependence on additional capital for operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sana Biotechnology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.